Amarin Corp Plc (AMRN)

[KCSVEN]

Anything is possible but JT said they would not let potential partners into the RI data because they did not want to distract from getting the filing done by end of Q1. I would assume that by saying partner that would also mean potential suitor.
Personally the direction of the company for the next year should be decided after Expedited review is likely granted, then whomever is going to be selling Vascepa after expended label will want to lay ground work, if Amarin is GIA they really need to start training and adding sales force well before expanded label.

I think we are in a bit of dead news spot until we get the FDA answer. Once that happens AMRN needs to decide on approach to marketing, Europe, potential BO etc...